SCHEMBL12875728

SCHEMBL12875728

Cc1cc(-c2csc(Cn3cc(C(=O)O)cn3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.39
PPARD Q03181 1/20 0.39
SIRT5 Q9NXA8 1/20 0.38
CFTR P13569 1/20 0.37
PTGER1 P34995 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198794 0.93 MEN1 (0.45) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1199036 0.89 MEN1 (0.42) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL12875727 0.89 KDM4E (0.44) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1198726 0.88 MEN1 (0.41) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1198657 0.88 MEN1 (0.41) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1198836 0.88 RXRA (0.42) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1198676 0.87 MEN1 (0.43) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL12875802 0.87 L3MBTL1 (0.39) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1198900 0.86 RXRA (0.42) ALDH1A1KDM4EMEN1KMT2AL3MBTL1
SCHEMBL1199543 0.86 ALDH1A1 (0.51) ALDH1A1KDM4EMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885KDM4E 1877/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.